It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
At Sygnature Discovery, we provide end-to-end GPCR solutions grounded in more than 20 years of cell signalling expertise.
GPCRs play a vital role in numerous physiological processes, making them essential targets for drug discovery. Our integrated approach brings together advanced assay platforms and tailored strategies to support receptor research at every stage.
With experience investigating over 250 GPCR targets and developing more than 100 validated cell lines, we deliver robust, reproducible insights through tools such as ligand binding, G protein interaction studies, β-arrestin recruitment, and secondary messenger analysis. Our expertise, from deorphanization to bias signalling, ensures you have the solutions you need to address complex receptor challenges.
Comprehensive Assay Solutions for GPCR Drug Discovery
Our in-house capabilities enable precise analysis of receptor signalling, protein interactions, and receptor internalization. We combine innovative technologies with proven expertise to deliver data-driven discovery and development.
Our assay portfolio includes:
• Radioligand binding
• Calcium mobilization
• cAMP measurements
• IP-1 quantification
• β-arrestin recruitment
• G protein dissociation
• Receptor internalization
• Receptor degradation
These tools allow us to interrogate bias signaling and measure key secondary messengers, driving confident decision-making throughout your program.
Integrated Drug Discovery Support
Seamless GPCR expertise from target to candidate. Our integrated GPCR platform combines cell signalling know-how, structural biology, and medicinal chemistry to accelerate candidate selection. From high-throughput screening to in vivo pharmacology, we deliver seamless, data-driven support to advance your target with confidence.
Custom GPCR Assay Development
Whether you need enhanced signal amplification, deorphanization support, or selective pathway bias profiling, our experienced team is on hand to drive your receptor research.
Assay Development
Every project is unique. Our dedicated scientists provide tailored assay solutions to address your specific challenges.
High-Throughput Screening
Cell-based signalling and functional assays designed to increase hit finding success.
Lead Optimization
Supporting medicinal chemistry campaigns we deliver optimized tools aligned with your receptor biology and discovery goals.
A versatile NanoBiT assay for ligand screening GPCRs remain key therapeutic targets, yet many –…
Posters
Related Capabilities
We bring together a dynamic blend of new talent and experiences pharmaceutical industry experts from around the world, delivering excellence across each stage of discovery.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
